Uncommon Cents Investing LLC Grows Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Uncommon Cents Investing LLC increased its holdings in Bristol-Myers Squibb (NYSE:BMY) by 13.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,305 shares of the biopharmaceutical company’s stock after buying an additional 1,260 shares during the quarter. Uncommon Cents Investing LLC’s holdings in Bristol-Myers Squibb were worth $559,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Northwest Financial Advisors bought a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at $27,000. Pacific Capital Wealth Advisors Inc. purchased a new position in Bristol-Myers Squibb during the fourth quarter valued at $34,000. VisionPoint Advisory Group LLC grew its holdings in Bristol-Myers Squibb by 300.5% during the third quarter. VisionPoint Advisory Group LLC now owns 737 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 553 shares during the period. Turtle Creek Wealth Advisors LLC purchased a new stake in Bristol-Myers Squibb in the fourth quarter worth about $40,000. Finally, Wetzel Investment Advisors Inc. purchased a new stake in Bristol-Myers Squibb in the fourth quarter worth about $40,000. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Price Performance

NYSE BMY traded down $0.39 during trading on Thursday, hitting $40.06. 9,131,450 shares of the stock traded hands, compared to its average volume of 16,023,750. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. Bristol-Myers Squibb has a 12-month low of $39.63 and a 12-month high of $65.38. The firm has a 50-day simple moving average of $42.46 and a 200-day simple moving average of $47.91. The company has a market capitalization of $81.21 billion, a P/E ratio of -12.92, a price-to-earnings-growth ratio of 13.84 and a beta of 0.44.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The firm had revenue of $11.87 billion during the quarter, compared to analyst estimates of $11.45 billion. During the same period last year, the firm posted $2.05 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was up 4.7% compared to the same quarter last year. As a group, analysts predict that Bristol-Myers Squibb will post 0.58 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Friday, July 5th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.99%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Analysts Set New Price Targets

BMY has been the topic of a number of analyst reports. Wells Fargo & Company lifted their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research report on Thursday, April 18th. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 27th. BMO Capital Markets lowered their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research note on Friday, April 26th. Finally, William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $60.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.